CRISPR Therapeutics AG (NASDAQ:CRSP)
| 65.03 Delayed Data As of Jun 02 |  +0.51 / +0.79%Today’s Change | 38.94 Today|||52-Week Range 86.95 | +59.98% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $5.1B |
Company Description
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Contact Information
CRISPR Therapeutics AG Baarerstrasse 14 Zug Zug 6300 |
Employees
Shareholders
| Mutual fund holders | 46.68% |
| Other institutional | 23.61% |
| Individual stakeholders | 22.95% |
Top Executives
| Rodger Novak | Chairman & President |
| Samarth Kulkarni | Chief Executive Officer & Executive Director |
| Raju Prasad | Chief Financial & Accounting Officer |
| Jonathan Alexander Terrett | Head-Research |
| Stephen R. Kennedy | Head-Technical Operations |
